Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH ...Middle East

PR Newswire - News
New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure. Current approved medications mainly address the symptoms of this rare condition....

Hence then, the article about chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against emap ii as potential treatment for pah was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH )

Apple Storegoogle play

Last updated :

Also on site :